CoChat

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Open access
Gorman, Matthew J., Patel, Nita, Guebre-Xabier, Mimi, Zhu, Alex L., Atyeo, Caroline, Pullen, Krista M., Loos, Carolin, Goez-Gazi, Yenny, Carrion, Ricardo, Tian, Jing-Hui, Yuan, Dansu, Bowman, Kathryn A., Zhou, Bin, Maciejewski, Sonia, McGrath, Marisa E., Logue, James, Frieman, Matthew B., Montefiori, David, Mann, Colin, Schendel, Sharon, Amanat, Fatima, Krammer, Florian, Saphire, Erica Ollmann, Lauffenburger, Douglas A., Greene, Ann M., Portnoff, Alyse D., Massare, Michael J., Ellingsworth, Larry, Glenn, Gregory, Smith, Gale, Alter, Galit · 2021 · Cell Reports Medicine
Cited by 129

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thus, we profiled the humoral immune response in a cohort of non-human primates immunized with a recombinant SARS-CoV-2 spike glycoprotein (NVX-CoV2373) at two doses, administered as a single- or two-dose regimen. Both antigen dose and boosting significantly altered neutralization titers and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were associated with distinct levels of protection in the upper and lower respiratory tract. Moreover, NVX-CoV2373 elicited antibodies that functionally targeted emerging SARS-CoV-2 variants. Collectively, the data presented here suggest that a single dose may prevent disease via combined Fc/Fab functions but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2021.100405

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 39

  1. Huff, 2020, Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies, Clin. Infect. Dis., 71, 2752, 10.1093/cid/ciaa654 · DOI · Paper page
  2. Day, 2020, Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village, BMJ, 368, m1165, 10.1136/bmj.m1165 · DOI · Paper page
  3. Meng, 2020, Intubation and ventilation amid the COVID-19 outbreak: Wuhan’s experience, Anesthesiology, 132, 1317, 10.1097/ALN.0000000000003296 · DOI · Paper page
  4. Poland, 2020, SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates, Lancet, 396, 1595, 10.1016/S0140-6736(20)32137-1 · DOI · Paper page
  5. 2021, UK science advisers: publish evidence behind COVID vaccine changes, Nature, 589, 169, 10.1038/d41586-021-00045-8 · doi:10.1038/d41586-021-00045-8
  6. Loos, 2020, Evolution of early SARS-CoV-2 and cross-coronavirus immunity, MSphere, 5, e00622-20, 10.1128/mSphere.00622-20 · DOI
  7. Brunet-Ratnasingham, 2021, Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality, medRxiv
  8. Bournazos, 2017, Diversification of IgG effector functions, Int. Immunol., 29, 303, 10.1093/intimm/dxx025 · DOI · Paper page
  9. Bournazos, 2015, Fcγ receptor pathways during active and passive immunization, Immunol. Rev., 268, 88, 10.1111/imr.12343 · DOI · Paper page
  10. Bournazos, 2020, The role of IgG Fc receptors in antibody-dependent enhancement, Nat. Rev. Immunol., 20, 633, 10.1038/s41577-020-00410-0 · DOI · Paper page
  11. Crowley, 2019, Mind the gap: how interspecies variability in IgG and Its receptors may complicate comparisons of human and non-human primate effector function, Front. Immunol., 10, 697, 10.3389/fimmu.2019.00697 · DOI · Paper page
  12. Plotkin, 2021, Accelerate COVID-19 vaccine rollout by delaying the second dose of mRNA vaccines, Clin. Infect. Dis., ciab068
  13. Kadire, 2021, Delayed second dose versus standard regimen for COVID-19 vaccination, N. Engl. J. Med., 384, e28, 10.1056/NEJMclde2101987 · DOI
  14. Matrajt, 2021, Optimizing vaccine allocation for COVID-19 vaccines: critical role of single-dose vaccination, medRxiv
  15. Barrett, 2021, Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses, Nat. Med., 27, 279, 10.1038/s41591-020-01179-4 · DOI · Paper page
  16. Tauzin, 2021, A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses, bioRxiv
  17. Ullah, 2021, Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy, bioRxiv
  18. Mahase, 2020, Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows, BMJ, 371, m4826, 10.1136/bmj.m4826 · DOI
  19. Ledford, 2021, J&J’s one-shot COVID vaccine offers hope for faster protection, Nature
  20. Iwasaki, 2017, Early local immune defences in the respiratory tract, Nat. Rev. Immunol., 17, 7, 10.1038/nri.2016.117 · DOI · Paper page
  21. Subbarao, 2020, Respiratory virus infections: understanding COVID-19, Immunity, 52, 905, 10.1016/j.immuni.2020.05.004 · DOI · Paper page
  22. Sealy, 2016, Antibody-secreting cells in respiratory tract tissues in the absence of eosinophils as supportive partners, Int. Immunol., 28, 559, 10.1093/intimm/dxw035 · DOI
  23. Kato, 2013, B-lymphocyte lineage cells and the respiratory system, J. Allergy Clin. Immunol., 131, 933, 10.1016/j.jaci.2013.02.023 · DOI · Paper page
  24. Chiu, 2015, Antiviral B cell and T cell immunity in the lungs, Nat. Immunol., 16, 18, 10.1038/ni.3056 · DOI
  25. Callaway, 2020, The coronavirus is mutating—does it matter?, Nature, 585, 174, 10.1038/d41586-020-02544-6 · DOI · Paper page
  26. Lee, 2020, Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant, bioRxiv
  27. Santos, 2021, The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation, bioRxiv
  28. Mahase, 2020, Covid-19: What have we learnt about the new variant in the UK?, BMJ, 371, m4944, 10.1136/bmj.m4944 · DOI
  29. Zhou, 2021, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell, 184, 2348, 10.1016/j.cell.2021.02.037 · DOI · Paper page
  30. Corey, 2020, A strategic approach to COVID-19 vaccine R&D, Science, 368, 948, 10.1126/science.abc5312 · DOI · Paper page
  31. Chandrashekar, 2020, SARS-CoV-2 infection protects against rechallenge in rhesus macaques, Science, 369, 812, 10.1126/science.abc4776 · DOI · Paper page
  32. Yu, 2021, Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques, Nature, 596, 423, 10.1038/s41586-021-03732-8 · DOI
  33. Alter, 2021, Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans, Nature, 596, 268, 10.1038/s41586-021-03681-2 · DOI · Paper page
  34. Lövgren, 1988, The requirement of lipids for the formation of immunostimulating complexes (iscoms), Biotechnol. Appl. Biochem., 10, 161, 10.1111/j.1470-8744.1988.tb00012.x · doi:10.1111/j.1470-8744.1988.tb00012.x
  35. Butler, 2019, A sample-sparing multiplexed ADCP assay, Front. Immunol., 10, 1851, 10.3389/fimmu.2019.01851 · DOI
  36. Karsten, 2019, A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis, J. Immunol. Methods, 471, 46, 10.1016/j.jim.2019.05.006 · DOI · Paper page
  37. Fischinger, 2019, A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation, J. Immunol. Methods, 473, 112630, 10.1016/j.jim.2019.07.002 · DOI · Paper page
  38. Gunn, 2018, A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus, Cell Host Microbe, 24, 221, 10.1016/j.chom.2018.07.009 · DOI · Paper page
  39. Brown, 2017, Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles, J. Immunol. Methods, 443, 33, 10.1016/j.jim.2017.01.010 · DOI · Paper page

Cited by

See all 129

Metadata

Authors
Gorman, M. J., Patel, N., Guebre-Xabier, M., Zhu, A. L., Atyeo, C., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., Yuan, D., Bowman, K. A., Zhou, B., Maciejewski, S., McGrath, M. E., Logue, J., Frieman, M. B., Montefiori, D., Mann, C., Schendel, S., Amanat, F., Krammer, F., Saphire, E. O., Lauffenburger, D. A., Greene, A. M., Portnoff, A. D., Massare, M. J., Ellingsworth, L., Glenn, G., Smith, G., & Alter, G.
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2021-09
Volume
2
Issue
9
Pages
100405
ISSN
2666-3791 (ISSN-L)
OpenAlex
W3198499417
Cited by
129
References
48
FWCI
8.37
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • National Science Foundation (1745302)
  • JPB Foundation (2020-215611 [5384])
  • Massachusetts Institute of Technology
  • Harvard University
  • Icahn School of Medicine at Mount Sinai
  • National Institutes of Health (1U01CA260476-01, 3R37AI080289-11S1, CIVIC75N93019C00052, R01AI146785, U19AI135995-02, U19AI42790-02S1)
  • Bill and Melinda Gates Foundation (INV-001650, OPP1146996)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. https://app.cochat.ai/papers/10.1016/j.xcrm.2021.100405
The paper
Gorman, M. J., Patel, N., Guebre-Xabier, M., Zhu, A. L., Atyeo, C., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., Yuan, D., Bowman, K. A., Zhou, B., Maciejewski, S., McGrath, M. E., Logue, J., Frieman, M. B., Montefiori, D., Mann, C., . . . Alter, G. (2021). Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2021.100405

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.